Inclusion Criteria Exclusion Criteria Timeline for a Trial Participant Screening Participants are screened for eligibility to participate in the trial Treatment Participants receive weekly subcutaneous injections of either CagriSema or Tirzepatide, with a dose escalation period followed by maintenance dosing Follow-up Participants are monitored for safety and effectiveness after treatment What Are the Treatments Tested in This Trial
Diabetes Journals E-prescribe: Send the device, sensors, and (if needed) reader via eNavvi for pickup or mail-order fulfillment to reduce friction and delays
That is exactly why physician supervision, full disclosure, and personalized treatment planning matter so much
Watanabe T, Sagisaka H, Arakawa S, Shibaya Y, Watanabe M, Igarashi I, et al
For peptides with particular sensitivity (e.g., copper-bound, hydrophobic) consider a pilot recon test in a small vial first